Steven Seedhouse
Stock Analyst at Raymond James
(1.99)
# 1,070
Out of 4,479 analysts
132
Total ratings
31.78%
Success rate
-6.64%
Average return
Main Sectors:
Top Industries:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics | Reiterates: Strong Buy | n/a | $55.32 | - | 14 | Jun 4, 2024 | |
| VERA Vera Therapeutics | Maintains: Strong Buy | $57 → $68 | $36.29 | +87.38% | 3 | May 10, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $34 → $51 | $28.87 | +76.65% | 2 | Apr 18, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $67 → $106 | $36.29 | +192.09% | 14 | Jan 11, 2024 | |
| ARDX Ardelyx | Maintains: Strong Buy | $12 → $15 | $7.57 | +98.15% | 2 | Jan 9, 2024 | |
| DYN Dyne Therapeutics | Maintains: Strong Buy | $27 → $56 | $35.49 | +57.79% | 4 | Jan 4, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $78 → $64 | $34.16 | +87.35% | 15 | Dec 19, 2023 | |
| LPTX Leap Therapeutics | Maintains: Outperform | $19 → $18 | $1.87 | +835.83% | 8 | Nov 14, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $78 → $57 | $22.47 | +153.67% | 7 | Nov 10, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Outperform | $5 → $4 | $1.65 | +142.42% | 5 | Nov 8, 2023 | |
| IFRX InflaRx | Maintains: Strong Buy | $21 → $19 | $1.72 | +1,004.65% | 9 | Nov 2, 2023 | |
| ZURA Zura Bio | Maintains: Strong Buy | $20 → $22 | $3.63 | +506.06% | 2 | Aug 15, 2023 | |
| WVE Wave Life Sciences | Initiates: Outperform | $7 | $5.24 | +33.72% | 1 | Jul 5, 2023 | |
| EDIT Editas Medicine | Upgrades: Outperform | $17 | $4.61 | +268.76% | 3 | Jun 13, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $33 → $35 | $20.66 | +69.41% | 4 | May 5, 2023 | |
| KYMR Kymera Therapeutics | Upgrades: Outperform | $38 | $30.95 | +22.78% | 2 | May 5, 2023 | |
| VBIV VBI Vaccines | Maintains: Outperform | $60 → $6 | $0.69 | +767.05% | 4 | Apr 13, 2023 | |
| ETNB 89bio | Maintains: Strong Buy | $25 → $50 | $7.76 | +544.33% | 7 | Mar 23, 2023 | |
| RNA Avidity Biosciences | Maintains: Strong Buy | $30 → $71 | $41.28 | +72.00% | 4 | Dec 15, 2022 | |
| GOSS Gossamer Bio | Maintains: Outperform | $15 → $5 | $0.95 | +427.65% | 5 | Dec 7, 2022 | |
| NEXI NexImmune | Downgrades: Market Perform | n/a | $2.58 | - | 4 | Nov 15, 2022 | |
| ANAB AnaptysBio | Maintains: Outperform | $30 → $38 | $24.61 | +54.41% | 2 | Nov 9, 2022 | |
| ARCT Arcturus Therapeutics Holdings | Downgrades: Underperform | n/a | $23.66 | - | 4 | Aug 10, 2022 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Market Perform | n/a | $0.29 | - | 2 | May 18, 2022 | |
| GILD Gilead Sciences | Downgrades: Sell | n/a | $68.64 | - | 3 | May 1, 2020 | |
| BIIB Biogen | Downgrades: Sell | n/a | $231.77 | - | 2 | Apr 23, 2020 |
Viking Therapeutics
Jun 4, 2024
Reiterates: Strong Buy
Price Target: n/a
Current: $55.32
Upside: -
Vera Therapeutics
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $36.29
Upside: +87.38%
Dianthus Therapeutics
Apr 18, 2024
Maintains: Outperform
Price Target: $34 → $51
Current: $28.87
Upside: +76.65%
Apellis Pharmaceuticals
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $36.29
Upside: +192.09%
Ardelyx
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $7.57
Upside: +98.15%
Dyne Therapeutics
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $35.49
Upside: +57.79%
Mirum Pharmaceuticals
Dec 19, 2023
Maintains: Strong Buy
Price Target: $78 → $64
Current: $34.16
Upside: +87.35%
Leap Therapeutics
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $1.87
Upside: +835.83%
Intellia Therapeutics
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $22.47
Upside: +153.67%
ProQR Therapeutics
Nov 8, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $1.65
Upside: +142.42%
InflaRx
Nov 2, 2023
Maintains: Strong Buy
Price Target: $21 → $19
Current: $1.72
Upside: +1,004.65%
Zura Bio
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $3.63
Upside: +506.06%
Wave Life Sciences
Jul 5, 2023
Initiates: Outperform
Price Target: $7
Current: $5.24
Upside: +33.72%
Editas Medicine
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $4.61
Upside: +268.76%
Rocket Pharmaceuticals
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $20.66
Upside: +69.41%
Kymera Therapeutics
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $30.95
Upside: +22.78%
VBI Vaccines
Apr 13, 2023
Maintains: Outperform
Price Target: $60 → $6
Current: $0.69
Upside: +767.05%
89bio
Mar 23, 2023
Maintains: Strong Buy
Price Target: $25 → $50
Current: $7.76
Upside: +544.33%
Avidity Biosciences
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $41.28
Upside: +72.00%
Gossamer Bio
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.95
Upside: +427.65%
NexImmune
Nov 15, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.58
Upside: -
AnaptysBio
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $24.61
Upside: +54.41%
Arcturus Therapeutics Holdings
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $23.66
Upside: -
Galmed Pharmaceuticals
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.29
Upside: -
Gilead Sciences
May 1, 2020
Downgrades: Sell
Price Target: n/a
Current: $68.64
Upside: -
Biogen
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $231.77
Upside: -